KRAS and colorectal carcinoma: The KRAS mutation rate is significantly higher than the value of 20.7% among 314 CRC patients from Taiwan, China (Liou et al., 2011), 22% among 202 CRC patients from the England (Naguib et al., 2010), 30.1% among 392 CRC patients from Switzerland (Zlobec et al., 2010), but similar to that previously reported in Guangzhou, China (43.9%, 25/57) (Mao et al., 2012).